Research highlights potential targets to help fight Crohn's disease

Affecting around 115,000 people in the UK alone, Crohn's disease is a lifelong condition which sees parts of the digestive system become inflamed. There is no precise cure and causes are believed to vary. But one indicator of the condition - an abnormal reaction of the immune system to certain bacteria in the intestines - has had new light shed on it thanks to scientists at the University of Plymouth.

The research has focused on different types of cells called macrophages, which are part of our immune system and are found in most tissues, where they patrol for potential harmful organisms and destroy them.

In inflammatory diseases, like Crohn's, macrophages mediate the inflammatory destruction of the gut. Just how the tissue reacts (inflammation or suppression) is dependent on the type of macrophage cell present, and how it is stimulated - and scientists have been trying to get to the bottom of this.

The new research has shown how different types of macrophage - one type being pro-inflammatory and the other being anti-inflammatory - exhibit quite different molecular mechanisms involved in switching off their functional behavior when bacteria are present.

And this difference, as study author Dr Andrew Foey explains, highlights the possibility of targeting and selectively suppressing the pro-inflammatory cells that drive diseases such as Crohn's Disease.

This small step in understanding of differential off-signaling of macrophage type may go hand-in-hand with understanding the relapsing/remitting presentation of Crohn's Disease. It is suggestive of future research endeavors in targeting macrophage responses in the treatment of inflammatory diseases - and it's a really positive step."

Dr Andrew Foey

Source:
Journal reference:

Foey, A. et al. (2019) Macrophage subsets exhibit distinct E. coli-LPS tolerisable cytokines associated with the negative regulators, IRAK-M and Tollip. PLOS ONE. doi.org/10.1371/journal.pone.0214681.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
AMSBIO offers new, best-in-class CAR-T cell range for research and immunotherapy